Ask the Editor: Ion Exchange
When is it acceptable to use a strong anion exchange HPLC column in place of a weak anion exchange column? Is it ever acceptable?
An LCGC reader recently submitted the following question:
When is it acceptable to use a strong anion exchange HPLC column in place of a weak anion exchange column? Is it ever acceptable?
The following answer was provided by Tom Jupille, president of LC Resources, Inc. (Walnut Creek, California).
The short answer: If you can demonstrate that it works, then it's acceptable . . . but don't hold your breath; you're unlikely to make it work without modifying other parameters such as pH, ionic strength, or mobile phase salt type.The longer answer: the terms "strong" and "weak" refer to the pKa of an ion exchanger, just as they do to any acid or base. A strong exchanger has a very low (acid) or high (base) pKa, and is therefore completely ionized at any reasonable intermediate pH. Examples would be sulfonate ("S") cation exchangers or quaternary ammonium ("Q") anion exchangers. A weak exchanger has an intermediate pKa; the degree of ionization varies over a 3-4 pH unit range around the pKa. Examples would be carboxymethyl (CM) cation exchangers or diethlyaminoethyl (DEAE) anion exchangers."Strong" and "weak" are often confused with "high capacity" and "low capacity." The capacity of an ion exchanger is the amount of charge per unit volume of column packing. It is quite possible to have a low-capacity strong exchanger or a high-capacity weak exchanger. The difference is that the capacity of a weak exchanger can be pH-dependent.If the operating pH of the method is near the pKa of a weak exchanger, then the chances of matching the ion exchange capacity in a strong exchanger range from slim to none. Even if you do match the capacity, secondary factors such as substrate chemistry, charge density of the ligand, and so forth come into play and make an exact match extremely difficult (in fairness, those same factors would apply even when substituting another weak exchanger).
Questions?
LCGC technical editor Steve Brown will answer your technical questions. Each month, one question will be selected to appear in this space, so we welcome your submissions. Please send all questions to the attention of "Ask the Editor" at lcgcedit@lcgcmag.com We look forward to hearing from you.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
